Scarica l'app Stockscreener
68.05
2.19%
-1.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$69.59
Aprire:
$69.25
Volume 24 ore:
524.24K
Relative Volume:
0.21
Capitalizzazione di mercato:
$9.48B
Reddito:
$181.74M
Utile/perdita netta:
$-143.97M
Rapporto P/E:
-48.96
EPS:
-1.39
Flusso di cassa netto:
$9.60M
1 W Prestazione:
+6.62%
1M Prestazione:
-2.53%
6M Prestazione:
+327.54%
1 anno Prestazione:
+216.14%
Intervallo 1D:
$67.92
$71.16
Intervallo di 1 settimana:
$61.65
$71.16
Portata 52W:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
68.03 | 9.70B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Research Analysts Set Expectations for ARWR Q2 Earnings - MarketBeat
B. Riley Raises Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $101.00 - MarketBeat
Arrowhead Pharma (ARWR): B. Riley Securities Raises Price Target Significantly | ARWR Stock News - GuruFocus
Maryland State Retirement & Pension System Reduces Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data - Insider Monkey
Arrowhead Pharma (ARWR) Sees Target Price Boost by HC Wainwright & Co. | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $100.00 Price Target at HC Wainwright - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Precision Trading with Arrowhead Pharmaceuticals Inc. (ARWR) Risk Zones - Stock Traders Daily
Aug Reactions: How does Alamo Group Inc score in quality rankingsTrade Risk Assessment & Weekly High Return Forecasts - baoquankhu1.vn
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results - Business Wire
RNAi Obesity Wins And REDEMPLO’s China Nod Could Be A Game Changer For Arrowhead (ARWR) - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory - Finviz
Published on: 2026-01-18 16:18:12 - baoquankhu1.vn
How REDEMPLO’s China Approval and New Capital Raises Will Impact Arrowhead Pharmaceuticals (ARWR) Investors - Sahm
Market Catalysts: How cyclical is Arrowhead Pharmaceuticals Incs revenue streamJuly 2025 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data - Sahm
Arrowhead Pharma stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Nordea Investment Management AB - MarketBeat
SG Americas Securities LLC Boosts Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Piper Sandler maintains an overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - MSN
ARWR September 18th Options Begin Trading - Nasdaq
Bayforest Capital Ltd Decreases Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Stock Analysis: A Biotech Gem with 17% Upside Potential - DirectorsTalk Interviews
PRN_FinancialWrapper | PR NewswireArrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events - FinancialContent
Arrowhead Pharma (ARWR) Price Target Raised by Piper Sandler | A - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given "Overweight" Rating at Piper Sandler - MarketBeat
Latham Advises on Arrowhead Pharmaceuticals Upsized Offerings of US$625 Million Convertible Senior Notes, and US$200 Million Common Stock and Pre-Funded Warrants - Legal Desire Media and Insights
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - MSN
Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference - MarketBeat
Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes - TipRanks
Arrowhead Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events - FinancialContent
Fund Flows: Is Arrowhead Pharmaceuticals Inc gaining market shareWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50 - MSN
A shot in the arm for the innovative drug sector! Piper Sandler bets on Arrowhead, the leader in 'gene silencing', predicting a 55% surge in its stock price. - 富途牛牛
Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - Finviz
Arrowhead Pharmaceuticals Reports Transformative Year-End Results - MSN
Will Arrowhead Pharmaceuticals Inc. stock recover faster than peers2025 Analyst Calls & Weekly Setup with High ROI Potential - ulpravda.ru
Technical Reactions to ARWR Trends in Macro Strategies - Stock Traders Daily
Oklahoma City NewsThe Oklahoman - FinancialContent
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data - Yahoo Finance
Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch - TipRanks
Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings - TipRanks
Arrowhead Pharmaceuticals (NASDAQ: ARWR) prices equity and 0% 2032 convertible notes offerings - Stock Titan
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock outperform benchmarksChart Signals & Advanced Technical Analysis Signals - ulpravda.ru
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Obesity Trial Progress And New REDEMPLO Approvals - Sahm
Will Arrowhead Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Earnings Recap & Weekly Market Pulse Updates - ulpravda.ru
How Arrowhead Pharmaceuticals Inc. (HDP1) stock moves in volatile trading sessions2025 Trading Volume Trends & Technical Pattern Based Signals - ulpravda.ru
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):